Document is current

Article History

Received: 9 November 2023

Revised: 10 January 2024

Accepted: 27 January 2024

First Online: 7 February 2024

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.The protocol was approved by the Ethics Committee of the Medical Faculty of Erlangen University Hospital (ref. numbers 297_17 B and 252_20 B). There was no use of animal research within this project.

: P.A.F. has received honoraria from Roche, Pfizer, Novartis, and Celgene. His institution conducts research for Novartis, Cepheid, and BioNTech. A.H. had an advisory role and received honoraria from BMS, MSD, Roche, Cepheid, Qiagen, Agilent, Diaceutics, Lilly, AstraZeneca, Boehringer Ingelheim, AbbVie, Jansen-Cilag, Pfizer, and Ipsen. R.E. has received honoraria from Roche, Eisai, Pfizer, BioNTech, Veracyte (PROCURE), Diaceutics, Mindpeak, AstraZeneca, MEDAC and Novartis. The institution of A.H. and R.E. conducted research for AstraZeneca, Roche, Janssen-Cilag, NanoString Technologies, Biocartis, ZytoVision, Novartis, Cepheid, Mindpeak, MSD, Gilead, palleos healthcare, Sanofi/Owkin, and BioNTech. P.G. has received honoraria from Novartis, MSD, and AstraZeneca. The other authors have no conflicts of interest to declare.